TY - JOUR
T1 - GIH clinical research 2003-2004
T2 - The year in review
AU - Camilleri, Michael
N1 - Funding Information:
Supported in part by grants #RO1-DK54681 and #K24-DK-02638 from the National Institutes of Health. M.C. has received a research grant (2000–2003) from Johnson and Johnson, which markets infliximab; however, the grant was for work unrelated to that drug or disease.
PY - 2004/12
Y1 - 2004/12
N2 - This article summarizes the clinical research advances in gastroenterology and hepatology that were reviewed during the Plenary Session of the American Gastroenterological Association's Annual Meeting in May 2004 in New Orleans, Louisiana. The clinical research advances included the efficacy of infliximab in the treatment of fistulizing Crohn's disease, survival after isolated intestinal transplantation, the role of endoscopic treatment of bleeding peptic ulcers and Barrett's esophagus, the recurrence of cancer after laparoscopic colectomy, the impact of microsatellite instability on the response to adjuvant chemotherapy with 5-fluorouracil (5-FU), the epidemiology of obesity and its response to low-carbohydrate diets, the potential role of gastrointestinal factors in the development of obesity, and, the newly appreciated condition, autoimmune pancreatitis with associated cholangitis. Clinical research advances will impact the management of digestive diseases.
AB - This article summarizes the clinical research advances in gastroenterology and hepatology that were reviewed during the Plenary Session of the American Gastroenterological Association's Annual Meeting in May 2004 in New Orleans, Louisiana. The clinical research advances included the efficacy of infliximab in the treatment of fistulizing Crohn's disease, survival after isolated intestinal transplantation, the role of endoscopic treatment of bleeding peptic ulcers and Barrett's esophagus, the recurrence of cancer after laparoscopic colectomy, the impact of microsatellite instability on the response to adjuvant chemotherapy with 5-fluorouracil (5-FU), the epidemiology of obesity and its response to low-carbohydrate diets, the potential role of gastrointestinal factors in the development of obesity, and, the newly appreciated condition, autoimmune pancreatitis with associated cholangitis. Clinical research advances will impact the management of digestive diseases.
UR - http://www.scopus.com/inward/record.url?scp=11144298732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11144298732&partnerID=8YFLogxK
U2 - 10.1016/S1542-3565(04)00448-3
DO - 10.1016/S1542-3565(04)00448-3
M3 - Review article
C2 - 15625646
AN - SCOPUS:11144298732
SN - 1542-3565
VL - 2
SP - 1043
EP - 1047
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 12
ER -